O
TSVT

OrbiMed’s 2seventy bio TSVT Stock Holding History

OrbiMed’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,391,628
Closed -$24.2M – 140
2023
Q2 		$24.2M Hold
2,391,628
– – 0.44% 63
2023
Q1 		$24.4M Buy
2,391,628
+1,350,328
+130% +$15.4M 0.48% 59
2022
Q4 		$9.76M Hold
1,041,300
– – 0.19% 76
2022
Q3 		$15.2K Buy
+1,041,300
New +$15.5M 0.28% 73

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

OrbiMed's TSVT Position: Q3 2023 in Review

OrbiMed sold out of 2seventy bio (TSVT) in Q3 2023, closing a stake of 2,391,628 shares — an estimated $24.2M sold.

OrbiMed first reported a position in TSVT in Q3 2022 and held it in 4 quarters. The position peaked at $24.4M in Q1 2023. 145 funds tracked by Wall St. Rank hold TSVT as of Q3 2023.

  • OrbiMed reported no remaining 2seventy bio position as of Q3 2023 after selling out during the quarter.
  • OrbiMed sold 2,391,628 2seventy bio shares in Q3 2023, an estimated $24.2M.
  • OrbiMed first reported a position in 2seventy bio in Q3 2022 and held it in 4 quarters.
  • OrbiMed's 2seventy bio position peaked at $24.4M in Q1 2023.
  • 145 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2023.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.